Recursion Pharmaceuticals Inc vs UnitedHealth Group Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while UnitedHealth Group Inc trades at $436 (market cap $382.83B). The key difference: UnitedHealth Group Inc is far larger — about 250.2× Recursion Pharmaceuticals Inc's market cap, and UnitedHealth Group Inc pays a 2.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | UNH | |
|---|---|---|
Market Cap | $1.53B | $382.83B |
Sector | Health | Health |
52-Week High | $6.79 | $431.68 |
52-Week Low | $2.84 | $237.77 |
Enterprise Value | $946.50M | $429.52B |
Dividend Yield | — | 2.2% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UnitedHealth Group (UNH) trades at $426.09, up 0.64% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $6.38 surpassing expectations of $4.94. Revenue growth remains robust, reaching $447.57 billion in 2025, though net margins have compressed to 2.68%. Recent corporate actions include a $2.32 dividend and ongoing share repurchases, while news highlights operational streamlining like reduced pediatric prior authorizations.
UNH's outlook is positive, driven by aging demographics and tech innovation in healthcare, offering upside to the $467.12 consensus target. Risks include regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. Institutional sentiment is strongly bullish, with 82.69% of analysts rating it a buy, supporting long-term growth prospects amid sector tailwinds.
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →